TY - JOUR
T1 - Cancer immunotherapy and application of nanoparticles in cancers immunotherapy as the delivery of immunotherapeutic agents and as the immunomodulators
AU - Debele, Tilahun Ayane
AU - Yeh, Cheng Fa
AU - Su, Wen Pin
N1 - Funding Information:
Funding: This research was funded by the Ministry of Science and Technology, Taiwan; grants number: MOST-110-2811-B-006-501, 108-2811-B-006-501, 108-2811-B-006-525, 109-2314-B-006-078, 109-2314-B-006-084-MY3, CMNCKU10806 & Headquarters of University Advancement, National Cheng Kung University, grant number: HUA 109-25-18-133.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/12
Y1 - 2020/12
N2 - In the last few decades, cancer immunotherapy becomes an important tactic for cancer treatment. However, some immunotherapy shows certain limitations including poor therapeutic targeting and unwanted side effects that hinder its use in clinics. Recently, several researchers are exploring an alternative methodology to overcome the above limitations. One of the emerging tracks in this field area is nano-immunotherapy which has gone through rapid progress and revealed considerable potentials to solve limitations related to immunotherapy. Targeted and stimuli-sensitive biocompatible nanoparticles (NPs) can be synthesized to deliver immunotherapeutic agents in their native conformations to the site of interest to enhance their antitumor activity and to enhance the survival rate of cancer patients. In this review, we have discussed cancer immunotherapy and the application of NPs in cancer immunotherapy, as a carrier of immunotherapeutic agents and as a direct immunomodulator.
AB - In the last few decades, cancer immunotherapy becomes an important tactic for cancer treatment. However, some immunotherapy shows certain limitations including poor therapeutic targeting and unwanted side effects that hinder its use in clinics. Recently, several researchers are exploring an alternative methodology to overcome the above limitations. One of the emerging tracks in this field area is nano-immunotherapy which has gone through rapid progress and revealed considerable potentials to solve limitations related to immunotherapy. Targeted and stimuli-sensitive biocompatible nanoparticles (NPs) can be synthesized to deliver immunotherapeutic agents in their native conformations to the site of interest to enhance their antitumor activity and to enhance the survival rate of cancer patients. In this review, we have discussed cancer immunotherapy and the application of NPs in cancer immunotherapy, as a carrier of immunotherapeutic agents and as a direct immunomodulator.
UR - http://www.scopus.com/inward/record.url?scp=85097819310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097819310&partnerID=8YFLogxK
U2 - 10.3390/cancers12123773
DO - 10.3390/cancers12123773
M3 - Review article
AN - SCOPUS:85097819310
VL - 12
SP - 1
EP - 24
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 12
M1 - 3773
ER -
